/
Oncology
Rare Tumor
30
Pipeline Programs↗
3
Active Trials↗
11
Companies Involved↗
Rare Tumor is an emerging landscape with 30 programs across 11 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., Base Therapeutics (Shanghai) Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 230
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
18 of 24 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.
Analysis
Trial Status
5
clinical trials
Terminated1 · 20%
Completed1 · 20%
Recruiting1 · 20%
Active, not recruiting1 · 20%
Not yet recruiting1 · 20%
Clinical Trials
Trial Activity
PLATFORM Study of Precision Medicine for Rare Tumors
Recruiting·—·Phase 2·NCT04423185·770 enrolled
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)